{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:18:19Z","timestamp":1787008699324,"version":"build-2736575974"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Type 1 diabetes is associated with excess cardiovascular risk. In contrast to type 2 diabetes, however, age at the onset of type 1 diabetes and sex are major predictors of cardiovascular risk, while the role of low-density lipoprotein cholesterol (LDL-C) and lipid-lowering therapy is less clear.<\/jats:p>\n                  <jats:p>Since most data on the effects of lipid-lowering treatments are obtained from randomized clinical trials that included very predominantly patients with type 2 diabetes, it is almost impossible to specifically discern endpoints in type 1 diabetes. Inversely, most data specific for type 1 diabetes are obtained from real world findings. Consequently, the evidence on efficacy and safety of lipid-lowering therapies available from randomized clinical trials arises very predominantly from type 2 diabetes. Thus, this specific review summarizes the evidence of lipid-lowering drug classes in reducing cardiovascular risk in patients with type 1 diabetes.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaf023","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T10:39:18Z","timestamp":1747823958000},"page":"380-386","source":"Crossref","is-referenced-by-count":3,"title":["Management of dyslipidaemia in patients with comorbidities\u2014facing the challenge: type 1 diabetes mellitus"],"prefix":"10.1093","volume":"11","author":[{"given":"Susanne","family":"Kaser","sequence":"first","affiliation":[{"name":"Medical University of Innsbruck Department of Internal Medicine I, , 6020 Innsbruck ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4612-117X","authenticated-orcid":false,"given":"Dobromir","family":"Dobrev","sequence":"additional","affiliation":[{"name":"Institute of Pharmacology, West German Heart and Vascular Center, University Duisburg-Essen , 45122 Essen ,","place":["Germany"]},{"name":"Montreal Heart Institute and Universit\u00e9 de Montr\u00e9al Department of Medicine and Research Center, , H1T 1C8 Montr\u00e9al ,","place":["Canada"]},{"name":"Baylor College of Medicine Department of Integrative Physiology, , 77030 Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8304-6423","authenticated-orcid":false,"given":"Bianca","family":"Rocca","sequence":"additional","affiliation":[{"name":"LUM University Department of Medicine, , 70010 Casamassima (BA) ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Kaski","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Molecular and Clinical Sciences Research Institute, St George's University of London , SW17 0RE London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[{"name":"Institute of Clinical Sciences, Karolinska Institute of Danderyd , 171 77 Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4677-9756","authenticated-orcid":false,"given":"Heinz","family":"Drexel","sequence":"additional","affiliation":[{"name":"Vorarlberg Institute for Vascular Investigation & Treatment (VIVIT) at the Academic Teaching Hospital Feldkirch , Carinagasse 47, 6800 Feldkirch ,","place":["Austria"]},{"name":"Private University in the Principality of Liechtenstein, Medical Sciences , Dorfstrasse 24, 9495 Triesen ,","place":["Liechtenstein"]},{"name":"Vorarlberger Landeskrankenhausbetriebsgesellschaft , 6800 Feldkirch ,","place":["Austria"]},{"name":"Drexel University College of Medicine , 2900 Queen Ln, Philadelphia PA 19129 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"2025070708265746900_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet"},{"key":"2025070708265746900_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1056\/NEJMc1706292","article-title":"Mortality and cardiovascular disease in type 1 and type 2 diabetes","volume":"377","author":"Rawshani","year":"2017","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib3","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMra2311526","article-title":"Prevention of cardiovascular disease in type 1 diabetes. Reply","volume":"390","author":"Manrique-Acevedo","year":"2024","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1007\/PL00002934","article-title":"Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes","volume":"44","author":"Morrish","year":"2001","journal-title":"Diabetologia"},{"key":"2025070708265746900_bib5","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2213-8587(14)70248-7","article-title":"Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis","volume":"3","author":"Huxley","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070708265746900_bib6","doi-asserted-by":"crossref","first-page":"117158","DOI":"10.1016\/j.atherosclerosis.2023.06.005","article-title":"Cardiovascular disease in type 1 diabetes, an underestimated danger: epidemiological and pathophysiological data","volume":"394","author":"Verg\u00e8s","year":"2024","journal-title":"Atherosclerosis"},{"key":"2025070708265746900_bib7","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1007\/s00125-017-4374-4","article-title":"The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT\/EDIC study","volume":"60","author":"Bebu","year":"2017","journal-title":"Diabetologia"},{"key":"2025070708265746900_bib8","doi-asserted-by":"crossref","first-page":"108141","DOI":"10.1016\/j.diabres.2020.108141","article-title":"Risk factors differ by first manifestation of cardiovascular disease in type 1 diabetes","volume":"163","author":"Miller","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"2025070708265746900_bib9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2337\/diacare.24.6.1053","article-title":"Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study","volume":"24","author":"Orchard","year":"2001","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/dme.13007","article-title":"LDL cholesterol is not a good marker of cardiovascular risk in type 1 diabetes","volume":"33","author":"Hero","year":"2016","journal-title":"Diabet Med"},{"key":"2025070708265746900_bib11","doi-asserted-by":"crossref","first-page":"e000719","DOI":"10.1136\/bmjdrc-2019-000719","article-title":"Adherence to lipid-lowering therapy and risk for cardiovascular disease and death in type 1 diabetes mellitus: a population-based study from the Swedish National Diabetes Register","volume":"8","author":"Hero","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2025070708265746900_bib12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jdiacomp.2016.01.018","article-title":"Lipoprotein composition in patients with type 1 diabetes mellitus: impact of lipases and adipokines","volume":"30","author":"Hughes","year":"2016","journal-title":"J Diabetes Complications"},{"key":"2025070708265746900_bib13","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.tem.2020.01.015","article-title":"Dyslipidemia in type 1 diabetes: a masked danger","volume":"31","author":"Verg\u00e8s","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"2025070708265746900_bib14","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2337\/dc16-0502","article-title":"Coprogression of cardiovascular risk factors in type 1 diabetes during 30 years of follow-up in the DCCT\/EDIC study","volume":"39","author":"Writing Group for the, D. E. R. G","year":"2016","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib15","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib16","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.116.025961","article-title":"Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus","volume":"135","author":"Rawshani","year":"2017","journal-title":"Circulation"},{"key":"2025070708265746900_bib17","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2337\/dc24-1023","article-title":"Cardiovascular complications, kidney failure, and mortality in young-onset type 1 and type 2 diabetes: data from the Korean National Health Insurance Service","volume":"48","author":"Kim","year":"2025","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib18","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib19","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib20","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ehjcvp\/pvad005","article-title":"The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes","volume":"9","author":"Johansen","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib21","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1093\/ehjcvp\/pvad037","article-title":"Focus on prevention in diabetes mellitus and lipid disorder","volume":"9","author":"Agewall","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"2025070708265746900_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2023.03.020","article-title":"Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: analysis of pooled data from four phase 3 clinical trials","volume":"373","author":"Stroes","year":"2023","journal-title":"Atherosclerosis"},{"key":"2025070708265746900_bib24","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0140-6736(22)01349-6","article-title":"Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune diseases and 12 cardiovascular diseases in 22 million individuals in the UK","volume":"400","author":"Conrad","year":"2022","journal-title":"Lancet"},{"key":"2025070708265746900_bib25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1186\/s12933-024-02544-0","article-title":"Genetic predisposition to nephropathy and associated cardiovascular disease in people with type 1 diabetes: role of the angiotensinI-converting enzyme (ACE), and beyond; a narrative review","volume":"23","author":"Mohammedi","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"2025070708265746900_bib26","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1161\/CIRCULATIONAHA.115.018844","article-title":"Prediction of first cardiovascular disease event in type 1 diabetes mellitus: the steno type 1 risk engine","volume":"133","author":"Vistisen","year":"2016","journal-title":"Circulation"},{"key":"2025070708265746900_bib27","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2337\/db18-0515","article-title":"Risk factor modeling for cardiovascular disease in type 1 diabetes in the Pittsburgh Epidemiology of Diabetes Complications (EDC) study: a comparison with the diabetes control and complications trial\/Epidemiology of Diabetes interventions and complications study (DCCT\/EDIC)","volume":"68","author":"Miller","year":"2019","journal-title":"Diabetes"},{"key":"2025070708265746900_bib28","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.2337\/dc06-0290","article-title":"Deficiencies of cardiovascular risk prediction models for type 1 diabetes","volume":"29","author":"Zgibor","year":"2006","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12933-022-01537-1","article-title":"Arterial stiffness in patients with type 1 diabetes and its comparison to cardiovascular risk evaluation tools","volume":"21","author":"Helleputte","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2025070708265746900_bib30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40292-020-00395-w","article-title":"Vascular aging and Central aortic blood pressure: from pathophysiology to treatment","volume":"27","author":"Battistoni","year":"2020","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"2025070708265746900_bib31","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.3390\/jcm10163616","article-title":"Arterial stiffness in type 1 diabetes: the case for the arterial wall itself as a target organ","volume":"10","author":"Gonz\u00e1lez-Clemente","year":"2021","journal-title":"J Clin Med"},{"key":"2025070708265746900_bib32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2337\/db15-0936","article-title":"In vivo platelet activation and aspirin responsiveness in type 1 diabetes","volume":"65","author":"Zaccardi","year":"2016","journal-title":"Diabetes"},{"key":"2025070708265746900_bib33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.numecd.2017.06.016","article-title":"Platelet indices and glucose control in type 1 and type 2 diabetes mellitus: a case-control study","volume":"27","author":"Zaccardi","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2025070708265746900_bib34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.2337\/dc15-2450","article-title":"Association between use of lipid-lowering therapy and cardiovascular diseases and death in individuals with type 1 diabetes","volume":"39","author":"Hero","year":"2016","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib35","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2025070708265746900_bib36","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists' (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"key":"2025070708265746900_bib37","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1186\/s12967-023-04691-6","article-title":"Impact of statin treatment on cardiovascular risk in patients with type 1 diabetes: a population-based cohort study","volume":"21","author":"Yoo","year":"2023","journal-title":"J Transl Med"},{"key":"2025070708265746900_bib38","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0140-6736(22)01545-8","article-title":"Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials","volume":"400","author":"Cholesterol Treatment Trialists, C","year":"2022","journal-title":"Lancet"},{"key":"2025070708265746900_bib39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2213-8587(24)00040-8","article-title":"Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis","volume":"12","author":"Cholesterol Treatment Trialists' Collaboration. Electronic address, c. n. o. a. u., and Cholesterol Treatment Trialists, C","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070708265746900_bib40","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.jacl.2016.04.012","article-title":"Statin treatment is associated with insulin sensitivity decrease in type 1 diabetes mellitus: a prospective, observational 56-month follow-up study","volume":"10","author":"Duvnjak","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2025070708265746900_bib41","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.2337\/dc19-0884","article-title":"Medication adherence during adjunct therapy with statins and ACE inhibitors in adolescents with type 1 diabetes","volume":"43","author":"Niechcia\u0142","year":"2020","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib42","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib43","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1161\/CIRCULATIONAHA.117.030950","article-title":"Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)","volume":"137","author":"Giugliano","year":"2018","journal-title":"Circulation"},{"key":"2025070708265746900_bib44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/ehjcvp\/pvad083","article-title":"Combination therapy with moderate-intensity atorvastatin and ezetimibe versus high-intensity atorvastatin monotherapy in patients treated with percutaneous coronary intervention in practice: assessing RACING generalizability","volume":"10","author":"Lee","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S0140-6736(22)00916-3","article-title":"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial","volume":"400","author":"Kim","year":"2022","journal-title":"Lancet"},{"key":"2025070708265746900_bib46","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib47","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/ehjcvp\/pvae025","article-title":"Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation","volume":"10","author":"Goodman","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib48","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1111\/dom.13384","article-title":"Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials","volume":"20","author":"Ganda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025070708265746900_bib49","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib50","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025070708265746900_bib51","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ehjcvp\/pvad019","article-title":"The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"9","author":"Imbalzano","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib52","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1111\/dom.13114","article-title":"Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial","volume":"19","author":"Leiter","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025070708265746900_bib53","doi-asserted-by":"crossref","first-page":"1339487","DOI":"10.3389\/fcvm.2024.1339487","article-title":"PCSK9 inhibition: from effectiveness to cost-effectiveness","volume":"11","author":"Mercep","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"2025070708265746900_bib54","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"2025070708265746900_bib55","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.2337\/dc20-1533","article-title":"Fenofibrate use is associated with lower mortality and fewer cardiovascular events in patients with diabetes: results of 10,114 patients from the Korean National Health Insurance Service cohort","volume":"44","author":"Jo","year":"2021","journal-title":"Diabetes Care"},{"key":"2025070708265746900_bib56","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/ehjcvp\/pvae005","article-title":"New data on NOVEL ORAL ANTICOAGULANT, SGLT2i, lipid treatment and genetics","volume":"10","author":"Agewall","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib57","doi-asserted-by":"crossref","first-page":"e15310","DOI":"10.1111\/dme.15310","article-title":"Design, recruitment and baseline characteristics of the LENS trial","volume":"41","author":"LENS Collaborative Group","year":"2024","journal-title":"Diabet Med"},{"key":"2025070708265746900_bib58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00125-024-06290-6","article-title":"Effect of fenofibrate on residual beta cell function in adults and adolescents with newly diagnosed type 1 diabetes: a randomised clinical trial","volume":"68","author":"Hostrup","year":"2025","journal-title":"Diabetologia"},{"key":"2025070708265746900_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12933-020-01094-5","article-title":"Omega-3 polyunsaturated fatty acid supplementation versus placebo on vascular health, glycaemic control, and metabolic parameters in people with type 1 diabetes: a randomised controlled preliminary trial","volume":"19","author":"O'Mahoney","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2025070708265746900_bib60","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/ehjcvp\/pvab048","article-title":"Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy","volume":"8","author":"Drexel","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025070708265746900_bib61","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/ehjcvp\/pvac049","article-title":"Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials","volume":"9","author":"Patti","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf023\/63264512\/pvaf023.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/4\/380\/63264512\/pvaf023.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/4\/380\/63264512\/pvaf023.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T08:27:14Z","timestamp":1751876834000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/4\/380\/8139920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5,21]]},"published-print":{"date-parts":[[2025,7,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf023","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,21]]}}}